Australian entrepreneur publicly details the complete process of designing mRNA cancer vaccines for pets using AI, involving 300GB of genetic data and multi-model collaboration

Odaily Planet Daily reported that Paul Conyngham, the founder of an Australian AI consulting firm, posted on the X platform, revealing the complete technical process of designing a personalized mRNA cancer vaccine for a pet dog using multiple AI chatbots. The dog was diagnosed with malignant mast cell cancer in May 2024, and approximately 300GB of data was obtained through whole-genome and RNA sequencing, with target screening, protein structure modeling, and vaccine sequence design completed through collaboration among ChatGPT, Gemini, and Grok, ultimately pinpointing the c-KIT gene mutation and identifying 7 new antigen targets.

The vaccine was prepared by a research team from the University of New South Wales and administered at the University of Queensland’s Veterinary School. The overall treatment plan includes the combined use of the mRNA vaccine, tyrosine kinase inhibitors, and PD-1 inhibitors, with the administration sequence planned with AI assistance. After starting treatment in December 2025, some tumors shrank within three months, but there were still unresponsive lesions that required surgical intervention. Experts pointed out that this case represents an individual practice and does not constitute a universal medical conclusion.